{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:42:43Z","timestamp":1775486563447,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pure red cell aplasia (PRCA) is one of the complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its main pathogenesis is immune dysfunction leading to erythrocytes destruction. Currently, there is no gold standard for PRCA after allo-HSCT. Umbilical cord blood (UCB) and mesenchymal stem cells (MSCs) have been widely used in hematological and immune system diseases due to their hematopoietic reconstitution and immunomodulatory functions. However, few studies about using UCB and MSCs to treat PRCA after allo-HSCT have been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>In this report, different cell therapy regimens of UCB and MSCs were used in 3 acute myeloid leukemia (AML) patients diagnosed with PRCA after allo-HSCT. Results showed that all patients achieved significant progress without adverse reactions or complications. Furthermore, Case 1 treated with UCB combined with umbilical cord MSCs (UC-MSCs), and Case 2 treated with 3 doses of UCB mononuclear cells (UCB-MNC) achieved earlier RBC transfusion independence (2 months and 2 weeks after cell therapy, respectively) than Case 3 treated with one unit of UCB (3 months after cell therapy).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This report provides cell therapy strategies using UCB\/UCB-MNC and UC-MSCs to treat PRCA after allo-HSCT. Our study demonstrates the safety and efficacy of 3 doses of UCB-MNC regimen and UCB combined with UC-MSCs regimen, providing a new treatment option for patients with PRCA after allo-HSCT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1585088","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:03:33Z","timestamp":1748948613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cord blood therapy for pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: case series and review"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruirui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binglei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingling","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangke","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengkuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.829670","article-title":"Prevalence of pure red cell aplasia following major ABO-incompatible hematopoietic stem cell transplantation","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2023.06.009","article-title":"Pure red cell aplasia: The second hundred years","volume":"366","author":"Means","year":"2023","journal-title":"Am J Med Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000441507","article-title":"ABO-mismatched allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Worel","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"B4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bjh.2013.160.issue-6","article-title":"Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation","volume":"160","author":"Aung","year":"2013","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1687","article-title":"Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation","volume":"98","author":"Bolan","year":"2001","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2450\/2017.0322-16","article-title":"Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation","volume":"16","author":"Tomac","year":"2018","journal-title":"Blood Transfus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0304-8","article-title":"Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies","volume":"86","author":"Helbig","year":"2007","journal-title":"Ann Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v193.4","article-title":"Pure red blood cell aplasia: patient management pitfalls in major ABO-incompatible haematopoietic cell transplantation","volume":"193","author":"Booth","year":"2021","journal-title":"Br J Haematol"},{"key":"B9","article-title":"Pure Red Cell Aplasia. 2024 Feb 24","volume-title":"StatPearls","author":"Mangla","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v193.4","article-title":"Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study","volume":"193","author":"Longval","year":"2021","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0375-2","article-title":"No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation","volume":"54","author":"Wada","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1386670","article-title":"Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review","volume":"14","author":"Metafuni","year":"2024","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v94.11","article-title":"Allogeneic stem cell transplantation for acquired pure red cell aplasia","volume":"94","author":"Halkes","year":"2019","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10421","article-title":"Successful treatment of acquired pure red cell aplasia (PRCA) by allogeneic peripheral blood stem cell transplantation","volume":"74","author":"Tseng","year":"2003","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2174\/011574888X290378240424075002","article-title":"Umbilical cord blood and UC-MSCs combined with low-dose immunosuppressant in the treatment of elderly patients with pure red cell aplastic: A case series","volume":"20","author":"Zhu","year":"2024","journal-title":"Curr Stem Cell Res Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2017.08.004","article-title":"Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Varela Gomez","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04236.x","article-title":"After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B","volume":"45","author":"Schetelig","year":"2005","journal-title":"Transfusion"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01124-6","article-title":"Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question","volume":"56","author":"Marco-Ayala","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.03.001","article-title":"Chinese expert consensus on the diagnosis and treatment of acquired pure red cell aplasia (2020)","volume":"41","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1470068","article-title":"The clinical characteristics and therapy response of patients with acquired pure red cell aplasia","volume":"23","author":"Fu","year":"2018","journal-title":"Hematology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.05.014","article-title":"Allogeneic unrelated non HLA matched umbilical cord blood transfusion for refractory immune cytopenia: results of a phase I clinical trial","volume":"44","author":"Hu","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B24","doi-asserted-by":"publisher","first-page":"862721","DOI":"10.1155\/2012\/862721","article-title":"Rapid Recovery from Chronic PRCA by MSC Infusion in Patient after Major ABO-Mismatched alloSCT","author":"Sergeevicheva","year":"2012","journal-title":"Case Rep Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0599-0","article-title":"Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation","volume":"88","author":"Fang","year":"2009","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldw059","article-title":"Stem cell therapy for ischemic heart diseases","volume":"121","author":"Yu","year":"2017","journal-title":"Br Med Bull"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/14653240510027190","article-title":"Biology of cord blood cells and future prospects for enhanced clinical benefit","volume":"7","author":"Broxmeyer","year":"2005","journal-title":"Cytotherapy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"103042","DOI":"10.1016\/j.arcmed.2024.103042","article-title":"Umbilical cord blood hematopoietic cells: from biology to hematopoietic transplants and cellular therapies","volume":"55","author":"Mayani","year":"2024","journal-title":"Arch Med Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-024-02065-y","article-title":"A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-069716","article-title":"Immunomodulatory properties of mesenchymal stromal cells","volume":"110","author":"Nauta","year":"2007","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-022-10429-6","article-title":"Paracrine factors released by stem cells of mesenchymal origin and their effects in cardiovascular disease: A systematic review of pre-clinical studies","volume":"18","author":"Mabotuwana","year":"2022","journal-title":"Stem Cell Rev Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575488","article-title":"Integrated analysis of transcriptome and secretome from umbilical cord mesenchymal stromal cells reveal new mechanisms for the modulation of inflammation and immune activation","volume":"11","author":"Cruz-Barrera","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.placenta.2017.04.003","article-title":"Immunomodulatory properties of human placental mesenchymal stem\/stromal cells","volume":"59","author":"Abumaree","year":"2017","journal-title":"Placenta"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749192","article-title":"Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3727\/096368914X676916","article-title":"Repeated administrations of human umbilical cord blood cells improve disease outcomes in a mouse model of Sanfilippo syndrome type III B","volume":"23","author":"Willing","year":"2014","journal-title":"Cell Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"147001","DOI":"10.1016\/j.brainres.2020.147001","article-title":"Multiple doses of umbilical cord blood cells improve long-term brain injury in the neonatal rat","volume":"1746","author":"Penny","year":"2020","journal-title":"Brain Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2012.0345","article-title":"Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-beta-associated neuropathology in Alzheimer mice","volume":"22","author":"Darlington","year":"2013","journal-title":"Stem Cells Dev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e31254","DOI":"10.1371\/journal.pone.0031254","article-title":"Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS","volume":"7","author":"Garbuzova-Davis","year":"2012","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.03.131","article-title":"Enhanced therapeutic effects on acute myocardial infarction with multiple intravenous transplantation of human cord blood mononuclear cells","volume":"168","author":"Yuan","year":"2013","journal-title":"Int J Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1323862","article-title":"Cord blood as a potential therapeutic for amyotrophic lateral sclerosis","volume":"17","author":"Garbuzova-Davis","year":"2017","journal-title":"Expert Opin Biol Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1585088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:03:36Z","timestamp":1748948616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1585088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":40,"alternative-id":["10.3389\/fonc.2025.1585088"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1585088","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"article-number":"1585088"}}